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The 2012 International Symposium on HIV and Emerging Infectious Diseases (ISHEID) provided a forum for
investigators to hear the latest research developments in the clinical management of HIV and HCV infections as
well as HIV-1 reservoirs and cure research. Combined anti-retroviral therapy (c-ART) has had a profound impact on
the disease prognosis of individuals living with HIV-1 infection. However, although these anti-retroviral regimens are
able to reduce plasma viremia to below the limits of detection for sustained periods of time, there is a rapid
recrudescence in plasma viremia if treatment is interrupted. Therefore, despite this potent anti-retroviral
suppression, HIV-1 is able to persist within the infected individual. The main 2012 ISHEID theme was, hence
“searching for an HIV cure”. In this report we not only give details on this main topic of the 2012 ISHEID but also
summarize what has been discussed in the areas of HIV epidemiology, access to care, antiretroviral therapy
management and recent progress in the therapy of HCV infection in patients with HIV.
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The 2012 International Symposium on HIV and Emer-
ging Infectious Diseases (ISHEID) was held in Mar-
seilles, France, on May 23–25. This congress attracted
more than 1,000 participants from all over the world
(70% outside France) and allowed detailed discussions
around current issues in HIV research and care. In this
summary, we focus on the epidemiological aspects, the
study of HIV reservoirs and the search for an HIV cure,
combined antiretroviral therapy (c-ART) management in
2012 and new therapies for patients coinfected by HCV.
Update on HIV epidemic, prevention and progress
towards universal access
Anna Mia Ekström reported recent changes in HIV inci-
dence, with a tendency to stability or decrease, except* Correspondence: alain.lafeuillade@ch-toulon.fr
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distribution, and reproduction in any mediumfor Eastern Europe and Central Asia [1]. A HIV concen-
trated epidemic developed in Bulgaria, among most at-
risk groups (IVDUs, MSM, prisoners and people from
Romania) [2]. Annual new infections dropped by 21%
since 1997, but in 2010 new infections (2.7 millions) still
exceeded AIDS-related deaths (1.8 millions), 97% of
them occurring in low- and middle-income countries
(LMIC) [3]. Three points were discussed: i) the difficulty
to measure HIV incidence using current methodologies
since HIV prevalence became a poor estimate of inci-
dence due to different factors including access to c-ART
and variable retention in c-ART programs affecting sur-
vival; ii) c-ART coverage is not a sufficient guide to
measure the success of scaling up to treatment since the
percentage of lost-to-follow up patients (LTFU) 48 months
after c-ART initiation varies from 20 to 45% in LMIC. The
drop-out problem affected also the success of PMTCT
programs, pointing the need to measure completion ra-
ther than enrolment into programs; iii) the real-tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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heavily impacted by health system factors resulting in a
drop from 90% efficacy to 19% effectiveness.
Yves Souteyrand presented the WHO targets for 2015
and the challenges that need to be addressed [4], includ-
ing increasing resources for HIV programs while redu-
cing inequities in LMIC. The global resources allocated
to HIV programs dropped from 16 to 15 billion USD for
the first time in 2010. To achieve universal access to c-
ART governments must be consistent with their engage-
ments. Although global c-ART coverage was 47% by the
end of 2010, geographic, demographic, socio-economic
and vulnerable groups-related inequities produced large
variations in coverage, from 10% in North Africa and the
Middle East to 63% in Latin America and the Caribbean.
Other key challenges consist in improving earlier access
to treatment and sustaining long-term treatment. Beside
the problem of LTFU, attention must be paid to reten-
tion in pre c-ART care where substantial LTFU is
reported from HIV-testing to ART initiation [5]. HIV
and STDs testing, CD4 cell counting and viral load at
the 1st visit in the HIV program in Mexico City resulted
in 51% detection increase but 60% of newly HIV-
diagnosed people were not linked to care [6].
The Treatment 2.0 framework [7] represents a com-
prehensive approach to achieve these goals, focused on 5
areas of actions: 1) optimize drug regimens; 2) improve
access to a package of simple affordable point-of-care
and other simplified diagnostics; 3) reduce treatment
costs; 4) improve delivery systems; 5) mobilize commu-
nities in HIV prevention, treatment, and human rights-
related issues. In the Karnataka province (India), coord-
ination between government and civil society partners
resulted in higher decentralization of ART delivery ser-
vices and increase in HIV diagnoses [8], with positive
impacts on reduction in LTFU, on adherence and on
strengthening primary and secondary health care service,
beneficial for program sustainability [9]. In 2010 in Ar-
menia, 73% of HIV diagnosed people were linked to
care, 46% started ART and 14.9% were LTFU. However,
57.7% of newly HIV-infected people were diagnosed
lately, pointing the need to reinforce this program for ef-
ficient entry into care [10].
Another issue to achieve universal access concerns
health policy decisions at governmental levels in the
context of financial constraints. YazdanYazdanpanah
asked how to best utilize available resources in LIC or
HIC. Cost-effectiveness analyses (CEA) are tools to assist
decision makers in choosing from among competing
alternatives, in situations of uncertainty and limited
resources for prioritizing the use of health care services,
but they are one component among others including
fairness, ethics, and political issues. Most CEAs focus on
more effective intervention that are often more expensiveand allow to consider whether the additional benefit is
worth the additional cost. They can be used to consider
optimal timing of ART initiation. Studies in South-Africa
[11] and France [12] showed that earlier treatments may
significantly reduce HIV burden and costs. CEAs were
used to evaluate HIV testing strategies [13] or pre-
exposure prophylaxis (PrEP) interventions, showing that
high PrEP efficacy in high HIV incidence populations is
cost-saving and cost-effective [14].
HIV treatment as prevention (TasP), contrarily to PrEP
strategies, is no more controversial today. Based on
results from numerous studies demonstrating TasP as a
potent tool to reduce HIV transmission, Joep Lange sta-
ted that implementation of TasP should not await fur-
ther efficacy trials and need national plans for TasP roll-
out. Although designated as the breakthrough of year
2011[15], TasP will not be enough to end the HIV epi-
demic [16]. The spectrum of engagement in HIV care in
USA showed that only 19% of HIV-infected people had
an undetectable viral load [17]. The challenge is to keep
everybody in treatment to lower HIV transmission rate
and decrease incidence, but also to treat earlier to
maximize individual and public health benefits. More-
over TasP should be scaled up in conjunction with other
effective HIV prevention interventions.
Mark Wainberg discussed results and controversies
about PrEP strategies that appeared to be the hottest
point of debate of this meeting [18]. Will the use of ART
before sexual exposure prevent HIV acquisition? Efficacy
was largely demonstrated in many in vitro experiments
and in monkey models. Human efficacy trials, based on
TenofovirW treatment versus placebo design, produced
inconsistent results.Of the 5 trials using oral daily PrEP,
2 failed to show a benefit (VOICE, Fem-PrEP) while
iPrex, TDF-2 and Partners Prep trials reported 44 to
75% reduction of HIV transmission, respectively. The
Caprisa trial, based on vaginal TenofovirW gel, resulted
in 39% transmission reduction [19]. Adherence was key
issue since detectable drug levels strongly correlated
with prophylactic effect. Several questions were raised: is
daily PrEP high adherence achievable? Although few re-
sistant viruses were described in these trials, the ques-
tion of emergence and spread of resistances must be
addressed. How to exclude acute infection before start-
ing any PrEP? Is there a risk of change in behavior that
could off-set the benefit of PrEP? Similar safer sex prac-
tices, fewer sexual partners and no difference in STDs
acquisition were observed among iPrex participants. Is
oral PrEP safe enough? Adverse events were significantly
more frequent in the TDF/FTC arm in the Fem-Prep
trial. Evidence for safety needs to be strongly addressed.
The PrEP strategies raised rightful fears considering the
current situation of the HIV epidemic: treatments are
for those who need them; other prevention strategies are
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related costs and re-allocate resources from research or
prevention fields.
Intermittent PrEP strategies could represent an alter-
native to daily PrEP. They are based on data from animal
models and from the Caprisa trial where intermittent
use of TDF gel was effective, whereas its daily use in
VOICE was ineffective. They could induce a better ad-
herence with a potentially better efficacy/safety ratio and
could be more cost-effective than daily PrEP. This hy-
pothesis will be tested in the ANRS IPERGAY trial [20].
There are not yet clear responses to these challenges
and further research to evaluate PrEP strategies is neces-
sary before concluding the debate.
HIV reservoirs & the search of an HIV cure
Animal models are crucial for a better understanding of
HIV persistence during therapy and for the development
of novel therapeutic strategies in the quest of a cure for
HIV/AIDS. While sterilizing cure is defined by complete
eradication of HIV infected cells from the body, func-
tional cure is defined by undetectable viremia without
antiretroviral therapy, no CD4 loss, no immunological
defects and no disease progression. Guido Silvestri
reviewed the similarities between HIV and pathogenic
SIV infection of macaques including chronic immune
activation, mucosal immune dysfunction, microbial
translocation and high levels of infection of central-
memory CD4+ T cells [21]. These non-human primate
models provide real opportunities for several reasons: (i)
identity, dose, and route of virus challenge are known
(ii) various clinical parameters such time of infection or
duration of c-ART can be controlled (iii) active and per-
sistent reservoirs can be fully characterized (iv) testing
of “risky” interventions is possible. Longitudinal collec-
tions of blood/tissue, as well as elective necropsy are
available for determining virologic and immunologic
parameters. Among limitations, challenge viruses (SIV,
SHIV) are not HIV and obtaining levels of virus suppres-
sion similar to these obtained in HIV-infected humans is
sometimes hard to achieve. To conclude, Guido Silvestri
discussed pros and cons of developing a standardized
non-human primate resource and underlined the need
of close collaboration between “monkey people” and
“human people”.
The sources of HIV persistence in c-ART-treated indivi-
duals could arise from residual ongoing viral replication
or resting CD4+ T cells (and/or other cellular reservoirs)
harboring stably integrated, transcriptionally silent but
replication-competent proviruses. Carine Van Lint
reviewed the multiple mechanisms that control HIV la-
tency at a molecular level [22]. Beside post-transcriptional
blockade via inefficient viral mRNA transport and inhibi-
tory miRNAs, several blockades occur at a transcriptionallevel. Strong preference for proviral integration in protein-
encoding transcriptionally active genes has been demon-
strated. Recent data indicate a modest preference for inte-
gration in the same transcriptional orientation as the host
gene, suggesting that transcriptional interference could
play a major role in the establishment and maintenance of
HIV-1 latency through different mechanisms (enhancer
trapping, promoter occlusion, steric hindrance). The chro-
matin organization of the provirus and the epigenetic con-
trol of the promoter region (histone acetylation and
methylation, DNA methylation) are also important. How-
ever, the high degree of methylation of HIV-1 promoters
from infected individuals receiving suppressive antiretro-
viral therapy was not confirmed in a recent study. The ab-
sence of inducible cellular transcription factors, such as
NF-KB and NFAT, that are excluded from the nuclei of
resting cells, the sequestration of P-TEFb in a HEXIM/
75 K sn RNA-bound inactive form and the absence of Tat
and Tat-associated factors are the other mechanisms that
maintain HIV-1 latency.
Several approaches can be used to reactivate viral la-
tency with the expectation that new cell infections can be
blocked in vivo by immune surveillance or antiretroviral
drugs. IL7 or PKC agonists like prostratin can induce cel-
lular transcription factors (STAT 5, NF-KB). HDACi (His-
tone deacyltransferase inhibitors) like SAHA (Vorinostat)
promote histone acetylation, HMTi (Histone methyltrans-
ferase inhibitors) like chaetocin decrease histone methyla-
tion and DNA methylation inhibitors like decitabine
decrease DNA methylation. HMBA induce the recruit-
ment of the kinase complex P-TEFb (Cyclin T1/CDK9) to
the HIV-1 promoter. Synergistic activation of HIV-1 ex-
pression by prostratin and vorinostat has been observed
in vitro. Similarly, synergistic activation of HIV-1 expres-
sion by prostratin and HMBA has been obtained. There-
fore one of the most promising strategies to target latent
reservoirs could reside in combinations of several families
of compounds (Figure 1).
Tae-Wook Chun reviewed the main basic and clinical
aspects of HIV reservoirs that were discovered during
the past two decades [23]. Understanding the mechan-
isms by which HIV persists in the face of potent anti-
retroviral therapy is crucial for developing strategies to
eliminate reservoirs and ultimately eradicate HIV.
Homeostatic expansion of latent viral reservoir is an im-
portant issue but recent infections due to residual HIV
replication, particularly in the gut lymphoid tissue, have
to be taken into account. In addition, cell-to-cell spread
of HIV permits ongoing replication despite antiretroviral
therapy. The use of HDACi (such as vorinostat) for pur-
ging HIV in latently infected, resting CD4+ T cells from
infected individuals on ART had a minimal impact com-
pared to prostratin and anti-CD3. Recent data indicate
that stimulation of patient CD8+ T cells with HIV gag
Figure 1 Different targets and drugs to reactivate proviral HIV-1 DNA from latency.
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and led to killing of vorinostat-treated cells. Therefore
reactivation of viral latency in vivo is probably insuffi-
cient to accelerate the death of the reactivated cell and
will require therapeutic vaccine to boost CTL responses
in patients undergoing purging protocols to eliminate
the latent reservoir. Gene therapy based on zinc-finger
nuclease-mediated elimination of HIV coreceptors and
stem cell transplantation from CCR5 delta 32 homozy-
gous donors can generate HIV-resistant CD4+ T cells
but important challenges need to be addressed.
Romas Geleziunas [24] discussed progress in the
search for small molecule activators of latent HIV. He
described a primary cell, HIV latency assay modified
from an original assay developed by Planelles of the Uni-
versity of Utah. In this assay, memory CD4+ T cells are
generated from naive T cells by antibody and cytokine
treatment and then infected with a luciferase encoding
HIV-1 variant that undergoes a single cycle of infection.
The assay exploits a codon optimized luciferase that
increases the sensitivity of the reactivation assay. The
assay has been miniaturized to 384 well plates and auto-
mated for high throughput screening employing ten
thousand cells per 20 uL well and 20 nL of compound.
The screening efforts have focused on HDACi. Histone
acetylation of the HIV-1 LTR is believed to be a major
mechanism through which transcription of the LTR is
blocked and inhibitors of histone deacetylases have been
demonstrated to activate latent HIV-1 in vitro. Vorino-
stat (SAHA) is an HDAC inhibitor and is a licensed drug
for the treatment of cutaneous T cell lymphoma.Toxicity profiles for SAHA are well described and two
clinical trials exploring the ability of SAHA to reactivate
latent HIV in vivo are currently being carried out by
David Margolis at the University of North Carolina and
Sharon Lewin at the University of Melbourne. Prelimin-
ary studies from Margolis laboratory indicate that SAHA
is able to reactivate latent HIV in vivo. Geleziunas
described results with the HDACi, Romidepsin that is
FDA approved for the treatment of cutaneous T cell
lymphoma. Remarkably, Romidepsin is a thousand fold
more potent then SAHA at inducing latent HIV and one
thousand to twenty thousand more potent in inhibiting
HDAC enzymatic activity. Romidepsin was able to acti-
vate HIV RNA production in twelve of thirteen HIV-1
infected subjects on suppressive c-ART. The average in-
crease in viral RNA was approximately 8.6 fold. There-
fore Romidepsin may be a better inducer of latent HIV
in vivo and its favorable toxicity profiles would allow
multiple dose studies. While this is an exciting develop-
ment, an overarching question is whether the increases
in viral RNA induced either by SAHA or Romidepsin
will be sufficient to raise the amount of viral protein ex-
pression in reactivated cell to levels that lead to viral
cytopathicity and/or elimination by cytotoxic T cells. Re-
cent work from the Siliciano laboratory [25] indicates
that after reversal of latency in vitro, reactivated resting
T cells survived viral cytopathic effects even in the pres-
ence of autologous cytotoxic T lymphocytes from most
patients on suppressive anti-retroviral therapy. There-
fore, reactivation of viral latency may not be effective at
eliminating the infected cell.
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Jupiter, Florida described a novel compound that
suppresses Tat-dependent HIV transcription [26]. Cortis-
tatin A is a naturally occurring steroidal alkaloid isolated
from marine sponges. Cortistatin A was originally shown
to exert anti-proliferative activity against human umbil-
ical vein endothelial cells and the laboratory of Valente
became interested in Cortistatin A because it has also
been described as a ligand of CDK11. Since the related
CDK9 plays an essential role in activation of transcrip-
tional elongation by HIV-1 Tat, Valente explored
whether Cortistatin A may inhibit Tat activity.Cortistatin
A was found to exert an inhibitory effect on acute HIV-
1 infection at nanomolar concentrations and to repress
transcription from the HIV promoter. Valente demon-
strated that Cortistatin A binds to the basic domain of
Tat and inhibits elongation from the HIV-1 promoter.
Intriguingly, Cortistatin A was found to inhibit HIV re-
activation from resting CD4 cells isolated from
individuals on suppressive anti-retroviral therapy. Fur-
thermore, Cortistatin A appeared to affect an irreversible
effect on viral transcription since removal of Cortistatin
A did not result in viral rebound. Therefore, Cortistatin
A warrants serious consideration as an agent that can
force HIV-1 into an irreversible state of latency. This ap-
proach would be fundamentally different from other
approaches aimed at reactivating viral latency in order
to purge infected cells.Cortistatin A may have the cap-
acity to induce a permanent state of latency in cells of
HIV-1 infected patients.
The laboratory of Tokameh Mahmoudi of Erasmus
University Medical Center in Rotterdam provided evi-
dence for the involvement of the Wnt signaling pathway
in transcriptional regulation of the HIV-1 LTR [27]. A
hallmark of Wnt signaling is stabilization of the tran-
scriptional co-activator beta-catenin. Beta-catenin then
regulates gene expression by binding members of the T-
cell-specific transcription factor/lymphoid enhancer-
binding factor 1 (TCF/LEF-1) family of transcription fac-
tors. Mahmoudi presented evidence that the HIV-1 LTR
contains TCF/LEF binding sites and this prompted an
investigation of the effect of Wnt activation on tran-
scription of the latent HIV-1 LTR. LiCl, an inhibitor of
Wnt signaling, was found to strongly synergize with val-
proic acid or SAHA in inducing reactivation of the la-
tent HIV-1 LTR in a cell line model of HIV-1 latency.
The level of activation of the latent LTR was found to
correlate with the remodeling of NUC-1 by high reso-
lution nucleosomal mapping. Regulators of the Wnt sig-
naling pathway provide an additional strategy with
which to promote reactivation of the latent LTR particu-
larly in combination with HDACi.
Santiago Moreno summarized ongoing clinical trials
aimed at reactivating viral latency in vivo [28].Disulfiramhas been shown to activate HIV transcription in in vitro
latency models of HIV. This prompted a pilot clinical
trial involving 14 patients on c-ART with plasma viral
loads below 50 copies/ml. Disulfiram was administrated
for two weeks and the frequency of latently infected cells
as well as residual viral viremia was measured during
disulfiram administration. Overall, disulfiram was safe
and well tolerated with few adverse events. Within two
hours of initial administration of disulfiram, there was a
significant increase in residual viremia from an average
of 30 copies/ml to between 60 and 70 copies/ml. No sig-
nificant changes in the size of the latent reservoir were
observed at these intervals. Moreno then went on to
summarize results from the SAHA trial being conducted
by David Margolis at the University of North Carolina in
Chapel Hill where SAHA administration resulted in a
mean 4.8 fold increase in viral RNA expression in mem-
ory T cells. In contrast, there was no effect on residual
viremia in this trial. Moreno also described a pilot clin-
ical trial employing Bryostatin-1 in a Jurkat cell line
model of HIV-1 latency. Bryostatin-1 has been show to
reactivate HIV-1 through the PKC-dependent pathway
and to down-regulate the expression of CD4 and
CXCR4. Bryostatin-1 also synergizes with HDACi, VPA,
and trichostatin A in reactivating HIV-1 latency. This
has prompted a pilot clinical trial with a single dose of
Bryostatin-1 followed by evaluation of latent cell reser-
voir size residual viremia and cell associated viral RNA.
This pilot trial is ongoing.
In addition to the obstacles posed by reservoir of la-
tently infected cells, a number of studies have raised the
possibility that incomplete viral suppression may permit
some degree of replenishment of the viral reservoir in
patients on ART. In collaboration with Timothy Schacker
and Ashley Haase at the University of Minnesota and
Courtney Fletcher at the University of Nebraska, Mario
Stevenson has been examining anti-retroviral therapy
impacts on tissue reservoirs for HIV-1[29]. Gut associated
lymphoid tissue (GALT) is the major site of viral replica-
tion in viremic patients since the majority of permissive
lymphocytes are located within GALT. However, the im-
pact of anti-retroviral therapy on this reservoir and viral
activity in this reservoir in patients on suppressive therapy
are not well understood.Stevenson and collaborators
obtained lymphoid tissue for viremic individuals initiating
c-ART. The virologic response was gauged by measuring
unintegrated forms of viral DNA including linear forms
and episomal forms (2-LTR circles). Within several weeks
of initiating therapy plasma viremia fell to undetectable
levels in all individuals. Despite this, unintegrated viral
genomes were poorly resolved by one month and six
months post initiation of anti-retroviral treatment and in
some individuals levels of unintegrated DNA at 6 months
exceed those at baseline or one-month intervals particularly
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concentrations in cells from lymphoid tissue were found to
be significantly lower than in cells from peripheral blood
obtained at the same intervals. These preliminary data indi-
cate discordance in the ability of anti-retrovirals to seques-
ter within cells of lymphoid tissue and this raises the
possibility that lymphoid tissue may provide conditions for
de novo viral infection in the face of anti-retroviral
suppression.
Clinical and therapeutic aspects
As Roy Gulick [30] pointed out in his presentation on
new antiretroviral drugs, the number of agents currently
pursued in phase 2 and 3 clinical trials is limited, and
among those only the attachment inhibitor BMS-663068
represents a novel class with a new mode of action. This
leaves little hope that novel compounds will overcome
the problems of current drugs in the near future.
Jean-Michel Pawlotsky [31] gave an overview over re-
cently available anti-HCV agents and compounds cur-
rently under development, as well as major clinical trials
and very promising pilot studies investigating these
agents and interferon-free regimens. As David Back [32]
pointed out in his presentation on drug – drug interac-
tions, the two recently licensed HCV protease inhibitors
have opened a new arena of pharmacokinetic interac-
tions with antiretroviral compounds, which are partly
very challenging. He also described several important
pharmacokinetic interactions between e.g. parenteral or
topical corticosteroids and clarified that cobicistat, the
novel pharmacokinetic booster contained in preparations
of elvitegravir, will pose new questions regarding com-
patibility with concomitant medication. He made clear
that the optimal use of these drugs requires an under-
standing of their interactions by physicians treating co-
infected patients, and that more studies are needed to
improve the strategies of dealing with those interactions.
In his presentation on salvage therapy in 2012, Stefano
Vella [33] made the point that very few subjects in the
developed world currently reach a level of treatment fail-
ure that would require their classification as true salvage
patients. However, in developing countries patients reach
the point beyond which no promising options are avail-
able much earlier due to economic constraints. He
argued that this gap should be closed by making options
for resistant viruses available in these settings and defin-
ing an optimal sequence of regimens.
Jürgen Rockstroh [34] presented on the issues regard-
ing timing of anti-viral therapy, choice of regimen, com-
plications, and HCV-treatment in HCV co-infected
patients. He clarified that the beneficial effects of early
ART clearly outweigh potential liver toxicities, but that
physicians should stay alerted to the possibility of yet
unexpected untoward effects, such as the association ofportal hypertension with didanosine use. The treatment
armamentarium for HIV now offers chances for regi-
mens with less interaction with novel anti-HCV com-
pounds, so that HCV coinfection may be managed
actively.
In his presentation on pharmacogenomics, Amalio
Telenti [35] outlined the wide-spread use of pharmaco-
genomics in other fields of medicine, the advances in the
HIV field, especially with respect to management of tox-
icity (e.g. efavirenz, atazanavir, abacavir) or cardiovascu-
lar risk. He criticized the exceptionalism with respect to
the application of genetic analyses to clinical medicine,
especially in Europe and made a strong case for moving
forward with the implementation of these diagnostic
tools.
The question of when to initiate c-ART was also
addressed in a presentation by Cécile Goujard [36] about
the ANRS C06 Primo cohort, in which 1450 patients
with primary HIV infection (PHI) have been included
until 12/2011, 52% of whom initiated antiretroviral ther-
apy at PHI. Of note, 77% of those included at a CD4
count of <500/μL showed progression to <350 CD4
cells/μL after two years, whereas none of the patients
included at >750 CD4 cells/μL showed progression. In
this cohort, the level of HIV DNA was an independent
predictor of progression. When comparing patients with
transient c-ART initiated at PHI with the SEROCO co-
hort, there was no obvious impact of c-ART on time off
therapy. She also described the interesting observation
of 14 cases in whom HIV RNA was persistently un-
detectable for more than 12 months following interrup-
tion of ART initiated at PHI. They did not find an
overrepresentation of the HLA class one alleles classic-
ally associated with elite control. The virological and im-
munological arguments for starting ART as early as
possible were elucidated by Jean-Pierre Routy [37] and
Joseph Wong [38]. They talked about viral persistence as
the principal obstacle to cure and made the point that
clinical trials investigating functional or sterilizing cure
will have to include analytical treatment interruptions.
For some of the hot topics in clinical HIV medicine,
the organizers selected the format of a pro and con de-
bate. Magnus Gisslén and Hans-Jürgen Stellbrink dis-
cussed the relevance of HIV-associated neurocognitive
disorders, Mark Wainberg and Mark Nelson took the
pro and con positions for PrEP, and Alain Lafeuillade
and Jean-Pierre Routy discussed the prospects of HIV
cure. The audience witnessed very lively discussions.
Their votes reflected some changes in opinion after the
discussions and provided a valuable feedback to the pre-
senters regarding the perception of their argumentation.
In a review of HCV treatment outcome in the Hepa-
titis session, Stanislas Pol [39] clarified the clinically very
important point that remodeling of fibrosis following
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fibrosis reversal is associated with improvement of life
expectancy. He clarified that ultrasound follow-up
should be continued in patients with lack of fibrosis re-
versal following SVR, because progression to hepatocel-
lular carcinoma may still occur in these subjects.
Viral hepatitis
The burden of viral hepatitis is enormous worldwide.
Hepatitis B virus (HBV) and HCV are by far the most fre-
quent agents of chronic viral hepatitis. Chronic HBV in-
fection affects 350 million people, being the highest
prevalence found in Asia. Of note, superinfection with the
hepatitis delta virus (HDV) in chronic HBsAg+ carriers
leads to chronic hepatitis delta, which is the most aggres-
sive form of viral hepatitis. A study from Taiwan that
examined 1,186 HBsAg+patients found anti-HDV anti-
bodies in up to 55% of 341 HIV-HBV coinfected indivi-
duals, stressing on the poor outcome of these patients.
Delta superinfection was associated with intravenous drug
use as well as with HCV coinfection [40]. Interestingly,
HDV genotype IV predominated among injecting drug
users whereas genotype II was the most frequent variant
in other individuals with hepatitis delta in Taiwan.
Around 2% of the world population is infected by
HCV, which represents 175 million people. The propor-
tion of persons aware of their HCV infection is esti-
mated to be below 40% in the United States and only
rise up to 60% in France. Therefore, active HCV diagno-
sis remains crucial at a time that treatment for chronic
hepatitis C has become much more successful following
the arrival of directly acting antivirals (DAA). As in HIV,
proper strategies pursuing “test and treat” should now
be implemented for hepatitis C.
There are several reasons to explain why hepatitis C
therapy in HIV-infected individuals attracted so much
attention at ISHEID 2012. First, overall one third of
HIV+ individuals are coinfected with HCV, being this
rate disproportionately higher among IVDUs or persons
who acquired the virus from contaminated blood pro-
ducts (i.e., hemophiliacs). Second, the way the new
hepatitis C antiviral agents are used reminds much what
we are already familiar in HIV therapeutics, considering
variables such as viral load, drug resistance, geno/sub-
types, viral kinetics, combination therapy, etc. [41].
Third, the pharmaceutical companies that are develop-
ing DAA are almost the same that already are marketing
antiretroviral agents [31]. So, broad overlap exists be-
tween HCV and HIV at multiple areas. Ultimately, a
shift in prescribers of the new HCV medications should
be expected in many places moving from classical gas-
troenterologists to infectious diseases doctors.
Despite the previous considerations, significant bio-
logical features distinguish HIV from HCV, whichtranslate into clinical and therapeutic differences [31].
First, in contrast with HIV there is no integration of the
HCV genetic material into the chromosomes of infected
cells during the virus replication cycle. This explains
why HCV can be eradicated from the infected carrier
whereas there is no elimination feasible for HIV even in
long-term suppressed persons on antiretroviral therapy
[42]. Second, the genetic variability in HCV is much
greater than in HIV, accounting for significant differ-
ences in HCV susceptibility to antiviral agents across
distinct HCV genotypes and subtypes. For instance,
HCV subtype 1a responds less well to many DAA than
HCV subtype 1b. Moreover, selection of drug resistance
mutations to HCV protease inhibitors occurs at different
positions in HCV subtypes 1a versus 1b [43].
The management of chronic hepatitis C in the setting
of HIV infection is particularly challenging, being drug-
drug interactions, overlapping toxicities and difficulties
associated to polymedication amongst the most trouble-
some [41]. Both first-generation HCV protease inhibitors
boceprevir and telaprevir reduce significantly exposure
to HIV protease inhibitors but atazanavir for which this
effect is lower. Likewise, significant drug interactions
occur between telaprevir/boceprevir and HIV non-
nucleoside polymerase inhibitors nevirapine and efavir-
enz (Additional file 1: Table S1). However, rilpivirine and
etravirine do not interact significantly with DAA and
therefore can be safely co-administered [32]. The same
applies to raltegravir, which the most preferred third
antiretroviral agent for HIV-HCV coinfected patients
planned to be treated with DAA. Moreover, the good
safety liver profile of this drug makes it particularly at-
tractive for HIV-infected individuals with underlying
liver disease [34].
The results so far available with boceprevir and telapre-
vir in HIV/HCV-coinfected patients were deeply discussed
at ISHEID [41]. In the phase 2 boceprevir study, a total of
98 HCV genotype 1 patients were randomized to receive
either triple therapy or standard of care (peginterferon-
ribavirin) for one year. Two thirds of patients were
infected with HCV subtype 1a. Seven patients experienced
viral breakthrough during therapy, 3/64 in the boceprevir
arm and 4/34 in the control arm. Severe anemia devel-
oped in 5% of patients assigned to boceprevir and in 3% of
controls. Erythropoietin was prescribed in 38% of patients
on triple therapy and in 21% of controls. The rate of sus-
tained virological response 12 weeks after completion of
therapy (SVR12) was 61% versus 27%, respectively. Figure 2
records the proportion of patients with undetectable
HCV-RNA in the two study arms at different time points.
Although all patients were on antiretroviral therapy
(mostly HIV protease inhibitors), a similar proportion of
patients on boceprevir (3/64) and controls (4/34) experi-























Figure 2 Treatment of chronic hepatitis C withBoceprevir in HIV/HCV coinfected patients. P: pegylated interferon, R: ribavirin, SVR12:
sustained virological response at 12 weeks.
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http://www.aidsrestherapy.com/content/9/1/23In the phase 2 telaprevir trial (Study 110), 60 HIV-
infected patients coinfected with HCV genotype 1 were
randomized to receive either triple therapy or standard
of care (peginterferon plus ribavirin). Of note, telaprevir
only was given for the first 3 months of therapy, but all
patients received peginterferon-ribavirin for one year.
Thirteen patients did not receive antiretroviral therapy.
Of the rest, 24 were on efavirenz and 23 on atazanavir/r.
Early discontinuations due to side effects occurred in 3/
38 patients on telaprevir and 0/22 in the control arm.
Rash occurred in 13 (34%) patients on telaprevir and 5
(23%) controls. Anemia was recorded in 7 (18%) of
patients on telaprevir and 4 (18%) of controls. SVR12
was 74% (28/38) on triple therapy versus 45% (10/22) on
standard therapy. Relapses occurred in 1/32 (3%) of
patients on telaprevir and 2/13 (15%) controls. Patients
on atazanavir/r tended to respond better than those on
efavirenz, although the numbers were too low to draw
conclusions (Figure 3). All patients on antiretroviral
therapy kept on undetectable plasma HIV-RNA. The un-
explained high rate of response in controls might sug-
gest that the population enrolled in the 110 trial was



















Figure 3 Treatment of chronic hepatitis C with Telaprevir in
HIV/HCV coinfected patients. P: pegylated interferon, R: ribavirin.fact, the variation between triple therapy and standard of
care was more pronounced for boceprevir than telapre-
vir (35% versus 29%, respectively).
Successful treatment of hepatitis C translates into de-
finitive elimination of the virus from the body, and re-
gression of liver fibrosis occurs even in persons who
already had developed cirrhosis [44]. Cure has allowed
unveiling that chronic HCV infection results in other
abnormalities than hepatic inflammation and fibrosis.
This is the case for metabolic abnormalities, including
dislipidemia and insulin resistance, which ameliorate
once chronic hepatitis C is successfully treated. Likewise,
most autoimmune phenomena associated with persistent
HCV replication tend to resolve once the virus is cleared
with treatment. Finally, the recent appreciation of a
negative impact of persistent immune activation by
continuous HCV replication on body systems and
organs has encouraged to treat chronic hepatitis C even
in patients with minimal liver damage [45]. Again, learn-
ing from the consequences of uncontrolled viral replica-
tion in the HIV field is pushing the management of
hepatitis C.
Additional file
Additional file 1: Table S1. Pharmacological interactions between HCV
protease inhibitors and antiretroviral drugs.
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